Ocugen, Inc. 8K

Ocugen furnished an investor presentation describing progress and timelines for its late-stage ophthalmic gene therapy programs, targeting three BLA submissions by 2028 based on ongoing and planned pivotal trials for retinitis pigmentosa, Stargardt disease, and geographic atrophy.

Ocugen, Inc. furnished an investor presentation (Exhibit 99.1) outlining its gene therapy pipeline and projected regulatory timelines, highlighting three lead ophthalmic programs—OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy—with Phase 3 or pivotal Phase 2/3 trials in progress or initiated, favorable interim safety and efficacy data, and a corporate objective to file three Biologics License Applications (BLAs) with the FDA by 2028. The presentation emphasizes Ocugen’s modifier, gene‑agnostic platform aimed at addressing multiple inherited retinal diseases and advanced dry age-related macular degeneration via single subretinal injections, summarizes key clinical trial designs and endpoints, and details regulatory designations obtained (including RMAT, ODD, RPDD, ATMP, and OMPD) along with anticipated milestones such as trial enrollment completion, topline data readouts between 2026 and 2028, and subsequent BLA/MAA submissions. The company also contrasts its one-time gene therapies with currently approved chronic injectable therapies for geographic atrophy and underscores the potential to reduce treatment burden and improve access for patients globally.

Filing Facts

CIK

1372299

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-105968

Alert Tier

6